Endo acquires American Medical Systems for $2.9 billion in cash

NewsGuard 100/100 Score

Endo Pharmaceuticals (Nasdaq: ENDP) announced today the completion of its acquisition of American Medical Systems, Inc. (AMS).  Endo announced on April 11, 2011, that it entered into a definitive agreement to acquire AMS, a leading provider of world-class devices and therapies for male and female pelvic health, for approximately $2.9 billion in cash.

"Closing on this acquisition marks another milestone in the transformation of Endo and accelerates our strategy of building a diversified healthcare company, better able to respond to the changing economics that drive the U.S. healthcare environment," said Dave Holveck, president and CEO of Endo. "AMS accelerates our overall growth, and we are very excited about the potential of its current commercial portfolio, as well as potential new product introductions."

AMS brings Endo scale in its devices and services business segment, and the combination of AMS with Endo's existing platform will provide additional cost-effective solutions across the entire urology spectrum. It is expected that the combined company will deliver more comprehensive healthcare solutions across its diversified businesses in branded pharmaceuticals, generics, devices and services in key therapeutic areas, including pain and urology.  

Endo Pharmaceuticals expects to announce second quarter 2011 earnings in early August and will update full year 2011 financial guidance at that time.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aster DM Healthcare reveals top foods to combat PCOS symptoms